cognitive decline

Cambridge, Massachusetts, August 12, 2026 Leap Therapeutics has announced the publication of final results from its randomized Phase 2...

Austin, Texas, August 12, 2026 Function Health has announced a research partnership with NYU Grossman School of Medicine to...

LONDON, United Kingdom, July 15, 2026 New research presented at the Alzheimer’s Association International Conference (AAIC) 2026 has revealed...

LONDON, United Kingdom, July 13, 2026 GSK has announced positive interim results from the registrational Phase II AZUR-1 clinical...

NOVATO, California, July 13, 2026 Lighthouse Pharmaceuticals has announced new clinical findings from its Phase 2/3 GAIN trial, demonstrating...

MENLO PARK, California, July 13, 2026 PharmatrophiX, in collaboration with Indiana University School of Medicine, has presented encouraging new...

BETHESDA, Md., July 1, 2026 A National Institutes of Health (NIH)-funded study has identified a promising blood-based biomarker that...

CAMBRIDGE, Mass., May 14, 2026 Biogen Inc. has announced promising topline results from its Phase 2 CELIA study evaluating...

Boston, MA, USA – April 1, 2026 In a promising development for age-related cognitive decline and neurodegenerative disorders, Tiziana...

Phoenix, AZ – October 27, 2025: Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company, has issued...